Skip to main content
SpringerLink
Log in

Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?

  • Endocrine Imaging
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

We report on a 70-year-old man affected by radioiodine-refractory differentiated thyroid cancer (DTC) in whom metastases were treated by peptide receptor radionuclide therapy (PRRT). Seven years before, patient had undergone total thyroidectomy. Pathological examination was conclusive for DTC. The patient underwent some radioiodine treatments (RaIT). The last post-therapy whole body scan (pT-WBS) performed five days after RaIT did not show abnormal radioiodine uptake but serum thyroglobulin (Tg) value was high in absence of thyroglobulin-antibodies (Tg-Ab). In-111 DTPA-pentetreotide scintigraphy showed several lung lesions with high somatostatin receptor density. Patient underwent PRRT using Lu-177 DOTATOC. pT-WBS scan confirmed the metastases already demonstrated by In-111 DTPA pentetreotide but radioiodine negative.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. H. Budiawan, A. Salavati, H.R. Kulkarni, R.P. Baum, Peptide receptor radionuclide therapy of treatment-refractory metastatic thyroid cancer using (90)Yttrium and (177)Lutetium labeled somatostatin analogs: toxicity, response and survival analysis. Am. J. Nucl. Med. Mol. Imaging 4(1), 39–52 (2013)

    PubMed Central  PubMed  Google Scholar 

  2. B. Jois, R. Asopa, S. Basu, Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with 177Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of Chromogranin A level-positive neuroendocrine differentiation. Clin. Nucl. Med. 39(6), 505–510 (2014)

    Article  PubMed  Google Scholar 

  3. D.J. Kwekkeboom, E.P. Krenning, R. Lebtahi, P. Komminoth, B. Kos-Kudla, W.W. de Herder, U. Plockinger, Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society, ENETS Consensus Guidelines for the standards of care in neuroendocrine tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs. Neuroendocrinology 90(2), 220–226 (2009)

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors disclose no conflict of interest and no founding received for this work.

Author information

Authors and Affiliations

  1. Nuclear Medicine Unit, Department of Biomedical Sciences and of Morphological and Functional Images, Padiglione E, piano terra Policlinico Universitario “G. Martino” , University of Messina, v. Consolare Valeria, 98125, Messina, Italy

    Alfredo Campennì, Salvatore A. Pignata & Sergio Baldari

Authors
  1. Alfredo Campennì
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Salvatore A. Pignata
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sergio Baldari
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alfredo Campennì.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Campennì, A., Pignata, S.A. & Baldari, S. Can peptide receptor radionuclide therapy (PRRT) be useful in radioiodine-refractory differentiated thyroid cancer?. Endocrine 50, 516–518 (2015). https://doi.org/10.1007/s12020-014-0491-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-014-0491-8

Keywords

Search

Navigation